S P R Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 12-12-2024
- Paid Up Capital ₹ 0.10 M
as on 12-12-2024
- Company Age 19 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2022)
- Profit -45.00%
(FY 2022)
- Ebitda -45.00%
(FY 2022)
- Net Worth -6.51%
(FY 2022)
- Total Assets %
(FY 2022)
About S P R Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Veena Aggarwal and Indu Aggarwal serve as directors at the Company.
- CIN/LLPIN
U24232DL2005PTC137405
- Company No.
137405
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Jun 2005
- Date of AGM
02 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at S P R Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Veena Aggarwal  | Director | 30-Mar-2009 | Current |
| Indu Aggarwal | Director | 30-Mar-2009 | Current |
Financial Performance of S P R Pharmaceuticals.
S P R Pharmaceuticals Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 45% decrease in profit. The company's net worth dipped by a decrease of 6.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of S P R Pharmaceuticals?
In 2022, S P R Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sophisticated Industrial Materials Analytic Labs Private LtdActive 36 years 7 monthsIndu Aggarwal is a mutual person
- Pratham Garments Private LimitedActive 19 years 6 months
Veena Aggarwal and Indu Aggarwal are mutual person
- J A Pharmaceuticals Private LimitedActive 19 years 6 months
Veena Aggarwal and Indu Aggarwal are mutual person
- Sophisticated Industrial Consultants Private LimitedActive 29 years 10 months
Veena Aggarwal is a mutual person
- Our Dream Bar Private LimitedActive 8 years 10 months
Veena Aggarwal and Indu Aggarwal are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at S P R Pharmaceuticals?
Unlock and access historical data on people associated with S P R Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of S P R Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped S P R Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
